At a glance
- Originator Bristol-Myers Squibb
- Class Taxanes
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Adenocarcinoma; Breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours